O'Hara Fintan John, Costigan Conor, McNamara Deirdre
Department of Gastroenterology, Tallaght University Hospital, Dublin 24 D24 NR0A, Ireland.
Trinity Academic Gastroenterology Group, School of Medicine - Trinity College Dublin, Dublin 24 D24 NR0A, Ireland.
World J Gastrointest Endosc. 2024 Dec 16;16(12):661-667. doi: 10.4253/wjge.v16.i12.661.
Capsule endoscopy (CE) is a pivotal diagnostic tool for gastrointestinal (GI) disorders, yet capsule retention poses a significant risk, especially in patients with known risk factors. The patency capsule (PC) helps assess the functional patency of the GI tract to mitigate this risk. However, the standard 28-hour protocol for confirming patency often results in high false-positive rates, unnecessarily excluding many patients from undergoing diagnostic CE.
To investigate the use of a 72-hour extended patency protocol to improve functional patency rates in patients at risk of capsule retention.
We performed a prospective, open-label study evaluating an extended 72-hour protocol for confirming functional patency with the PC. Conducted over six months, 135 patients with risk factors for capsule retention were enrolled. The primary endpoint was the capsule retention rate in patients with confirmed functional patency. Secondary endpoints included the rates of confirmed patency self-reporting or radiology, small bowel transit times, and adverse events.
Functional patency was confirmed in 48.9% ( = 66) of patients within 28 hours, with an additional 17.4% ( = 12) confirmed within 72 hours, increasing the overall patency rate to 57.8%. There was no significant difference in small bowel transit time between patients confirmed for patency at 28 hours those confirmed at 72 hours. Importantly, no capsule retention was observed in patients who were confirmed for patency under the extended protocol. Notably, 50% ( = 39) of patients who proceeded to CE had clinically significant findings.
Extending the patency assessment protocol to 72 hours significantly improves the rate of confirmed functional patency without increasing the risk of capsule retention. This protocol is safe, effective, and cost-neutral, allowing more patients to benefit from CE. Further studies are recommended to refine the protocol and enhance its clinical utility.
胶囊内镜检查(CE)是诊断胃肠道(GI)疾病的关键工具,但胶囊滞留带来了重大风险,尤其是在具有已知风险因素的患者中。通畅性胶囊(PC)有助于评估胃肠道的功能通畅性以降低此风险。然而,用于确认通畅性的标准28小时方案常常导致高假阳性率,不必要地将许多患者排除在诊断性CE之外。
研究使用72小时延长通畅性方案来提高有胶囊滞留风险患者的功能通畅率。
我们进行了一项前瞻性、开放标签研究,评估用于确认PC功能通畅性的延长72小时方案。在六个月内进行,招募了135名有胶囊滞留风险因素的患者。主要终点是功能通畅得到确认的患者中的胶囊滞留率。次要终点包括通过自我报告或放射学确认的通畅率、小肠转运时间和不良事件。
48.9%(n = 66)的患者在28小时内功能通畅得到确认,另有17.4%(n = )在72小时内得到确认,使总体通畅率提高到57.8%。在28小时确认通畅的患者与72小时确认通畅的患者之间,小肠转运时间没有显著差异。重要的是,在延长方案下确认通畅的患者中未观察到胶囊滞留。值得注意的是,进行CE的患者中有50%(n = 39)有临床显著发现。
将通畅性评估方案延长至72小时可显著提高功能通畅得到确认的率,而不增加胶囊滞留风险。该方案安全、有效且成本中性,使更多患者能从CE中受益。建议进一步研究以完善该方案并提高其临床效用。